Iridium(<scp>iii</scp>) complexes as mitochondrial topoisomerase inhibitors against cisplatin-resistant cancer cells

Abstract

Herein, we developed the first metal-based mitochondrial topoisomerase inhibitors to achieve an effective therapeutic outcome for the therapy of cisplatin-resistant tumour cells.